United States: Online Article Need Not Be Indexed In A Database To Qualify As Publicly Available Prior Art

NB. This article is not published yet. Please try again later.

Authors
Events from this Firm
19 Jan 2017, Webinar, Washington, DC, United States

While the digital health industry promises a revolution in personalized healthcare by bringing together innovative software for healthcare data and cutting-edge life sciences advances, developing a meaningful patent portfolio around those innovations remains a challenge. Recent developments in the courts and at the USPTO have increased the difficulty of protecting those innovations, particularly where the underlying software or technology may build on “abstract ideas” or “laws of nature.”

24 Jan 2017, Speaking Engagement, Washington, DC, United States

The first webinar, gMaking the Biosimilar Business Case„ŸExploring the Interface Between Economics and Patent Lawh will explore both the economic market factors of the biosimilar world and patent strategies, and how they impact target selection for biologics and biosimilars.

24 Jan 2017, Webinar, Washington, DC, United States

This first webcast of our series will explore both the economic market factors of the biosimilar world and patent strategies, and how they impact target selection for biologics and biosimilars. In contrast to the development of generic small molecules, it has been reported that it takes seven to eight years to develop a biosimilar at a cost of between $100 million and $250 million.

 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter